2026 RNDS | Pediatric Case Series in Anti-Aquaporin-4 Antibody-Positive NMOSD @wearesrna
2026 RNDS | Pediatric Case Series in Anti-Aquaporin-4 Antibody-Positive NMOSD  @wearesrna
Uploaded October 2026 | Updated November 2026, 3 hours ago
In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Darina Dinov, DO, of Penn State University, spoke about pediatric neuromyelitis optica spectrum disorder (NMOSD) and how children have tolerated the treatment inebilizumab [00:00:05]. She compared pediatric and adult NMOSD, including the lack of FDA-approved medications for children and what off-label use can mean for insurance approval [00:01:40]. She explained the role of aquaporin-4 and B cells, and how inebilizumab reaches more of the cells that lead to antibody production than rituximab does [00:05:20]. Dr. Dinov presented a retrospective case series of four children, ages seven to 17, treated at UT Southwestern and Children's Dallas, all of whom tolerated their infusions [00:10:54]. She closed with what the findings may mean for families and clinicians seeking insurance approval, and the two ongoing pediatric trials [00:18:25].

Darina Dinov, DO, is a neurologist at Penn State University specializing in the diagnosis and treatment of diseases or impaired function of the brain, spinal cord, peripheral nerves, muscles, autonomic nervous system, and the blood vessels that relate to these structures. She is passionate about advancing our understanding through research, education, and innovation, and her work focuses on interdisciplinary approaches to solving complex problems and contributing to the scientific community.

00:00 Introduction
01:01 What Is NMOSD
01:40 Pediatric and Adult Similarities
03:17 No Approved Medications for Children
05:20 Aquaporin-4 and the Immune System
08:25 How Inebilizumab Works
10:54 The Four-Child Case Series
15:42 Results and Tolerability
16:52 Why Inebilizumab Matters
18:25 What This Means for Families and Clinicians
20:13 Ongoing Pediatric Trials and Thanks
2026 RNDS | Pediatric Case Series in Anti-Aquaporin-4 Antibody-Positive NMOSD1202. Increased Intracranial Pressure in Pediatric MOG Antibody Disease2023 RNDS | Rehabilitation and recovery2024 Stronger Together | Raising Funds for Rare2025 RNDS en Español | Cuidar al cuidador: conversación con un familiar2026 RNDS | Q-Cell Study Updates2026 RNDS | Spasticity Management and Mobility2025 RNDS en Español | Panel de aliados de la industria con Genentech1203. Community Spotlight | Rick TelanderCommunity Meets Clinic 303. Dr. Benjamin Greenberg2025 RNDS | Cognition, depression; psychological impacts and rare neuroimmune disorders1310.  Prevention and Treatment of Skin Breakdown
SRNA |

2026 RNDS | Pediatric Case Series in Anti-Aquaporin-4 Antibody-Positive NMOSD

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER